August 29, 2017
Cancer patients are being asked to pay more than they expected for treatment, despite having health insurance.
August 27, 2017
International prescription drug donation programs make a difference, explains a new white paper from the Global Alliance for Patient Access. But they could work even better.
August 17, 2017
The need for robust clinical trials participation is critical to women and men across this country, whether they know it or not.
July 20, 2017
Health plans often use different levels of cost sharing to drive patients toward one medication over another. But is this practice fair, ethical or effective in producing positive outcomes for patients? The answer, according to a recent National Pharmaceutical Council webinar panel, all depends.
July 11, 2017
It’s been over a year since the launch of former vice president Joe Biden’s Cancer Moonshot, designed to spur innovation and encourage collaboration on finding cures for cancer. So now, patients, physicians, researchers and policymakers are pausing to ask: Are we any closer?
June 6, 2017
For chronic migraine patients, the only thing better than making a headache stop is preventing it altogether. And new research suggests that patients may soon have new options for doing just that.
May 25, 2017
Is precision medicine gaining traction in the field of oncology? The Food and Drug Administration’s recent approval of the cancer drug pembrolizumab offers a hint.
May 10, 2017
When should patients switch from one medicine to another for non-medical reasons? How can pharmacovigilance processes successfully monitor patients’ reactions to a medicine? And, perhaps most importantly, how do we ensure that patients are informed participants in decisions about their medication?
April 18, 2017
Promising clinical trials data has excited patients with cystic fibrosis and their families. But will access barriers dash their hopes for more and better treatment options?
April 10, 2017
Physicians and patients are no longer asking if a biological medicine is the best choice, but – more likely – which biological medicine is the best choice. This opening thought from Alliance for Patient Access Chairman David Charles, MD, set the tone for the organization’s second annual National Policy and Advocacy Summit on Biologics and Biosimilars, held Thursday in Washington, DC.
